טוען...
Hyperprogressive disease after treatment with pembrolizumab in lung adenocarcinoma: An autopsy case study
Although immune-checkpoint inhibitors (ICIs) have become an important choice of treatment for advanced NSCLC, recent reports show hyperprogressive disease (HPD) after ICI administration. The clinico-pathological features of HPD still remain unclear. Here we report a 65-year-old man with lung adenoca...
שמור ב:
| הוצא לאור ב: | Respir Med Case Rep |
|---|---|
| Main Authors: | , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6586950/ https://ncbi.nlm.nih.gov/pubmed/31249779 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2019.100885 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|